Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster, Michael Russell Bishop, Constantine Si Lun Tam, Edmund K. Waller, Peter Borchmann, Joseph P. McGuirk, Ulrich Jaeger, Samantha Mary Jaglowski, Charalambos Babis Andreadis, Jason R. Westin, Isabelle Fleury, Veronika Bachanová, Stephen Ronan Foley, Phoebe Joy Ho, Stephan Mielke, John Martin Magenau, Harald Holte, Serafino Pantano, Lida Bubuteishvili Pacaud, Rakesh Awasthi, Jufen Chu, Özlem Anak, Gilles Andre Salles, Richard Thomas Maziarz
New England Journal of Medicine · 2018 · 4,230 citationsOpen access
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Schuster, S. J., Bishop, M. R., Tam, C. S. L., Waller, E. K., Borchmann, P., McGuirk, J. P., Jaeger, U., Jaglowski, S. M., Andreadis, C. B., Westin, J. R., Fleury, I., Bachanová, V., Foley, S. R., Ho, P. J., Mielke, S., Magenau, J. M., Holte, H., Pantano, S., Pacaud, L. B., … Maziarz, R. T. (2018). Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. New England Journal of Medicine, 380(1), 45–56. https://doi.org/10.1056/nejmoa1804980
In text: (Schuster et al., 2018)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
BACKGROUND: Patients with diffuse large B-cell lymphoma that is refractory to primary and second-line therapies or that has relapsed after stem-cell transplantation have a poor prognosis. The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and eliminates CD19-expressing B cells and showed efficacy against B-cell lymphomas in a single-center, phase 2a study. METHODS: We conducted an international, phase 2, pivotal study of centrally manufactured tisagenlecleucel involving adult patients with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for or had disease progression after autologous hematopoietic stem-cell transplantation. The primary end point was the best overall response rate (i.e., the percentage of patients who had a complete or partial response), as judged by an independent review committee. RESULTS: A total of 93 patients received an infusion and were included in the evaluation of efficacy. The median time from infusion to data cutoff was 14 months (range, 0.1 to 26). The best overall response rate was 52% (95% confidence interval, 41 to 62); 40% of the patients had complete responses, and 12% had partial responses. Response rates were consistent across prognostic subgroups. At 12 months after the initial response, the rate of relapse-free survival was estimated to be 65% (79% among patients with a complete response). The most common grade 3 or 4 adverse events of special interest included cytokine release syndrome (22%), neurologic events (12%), cytopenias lasting more than 28 days (32%), infections (20%), and febrile neutropenia (14%). Three patients died from disease progression within 30 days after infusion. No deaths were attributed to tisagenlecleucel, cytokine release syndrome, or cerebral edema. No differences between response groups in tumor expression of CD19 or immune checkpoint-related proteins were found. CONCLUSIONS: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use of tisagenlecleucel. (Funded by Novartis; JULIET ClinicalTrials.gov number, NCT02445248 .).
Related papers
- Integrated analysis of multimodal single-cell data2021
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer2012
- Control of Regulatory T Cell Development by the Transcription Factor Foxp32003
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer2012
- Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.1986
Metadata from OpenAlex (CC0). Citations are generated from the published record.